Cipla Ltd News Today

At the end of the inspection, the US FDA issued a Form 483 with one observation which was received at the conclusion of the inspection during the closing meeting.

The EBITDA margin saw a considerable improvement, moving up 184 basis points to 22.84%, from 21% in Q4 FY23.

For the quarter, net profit soared 49% on-year to ₹1,570 crore, on the back of higher revenue and better operating efficiency.

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market

The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.

Cipla reported a net profit of ₹1,303 crore, marking a 15% increase compared to the same period last year.

The VAI designation now clears the way for significant specialised launches, such as the Abraxane generic.

The company is now able to pursue important speciality medicine launches because to its VAI classification.

Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Tata Power, Biocon, etc.